

Need for alternative treatment in leprosy in the face of drug induced hepatitis

H F S Fonseka¹, I L Mahil², M Dissanayake³

Sri Lanka Journal of Dermatology, 2009, 13, 29

Introduction

Conventional multibacillary treatment regime (MBT) has been effective for leprosy¹, but all three drugs used in MBT namely dapsone, rifampicin and clofazimine can induce hepatitis. Second line treatments such as ofloxacin and clarithromycin too can be hepatotoxic.

Here we report a patient with borderline lepromatous leprosy who developed hepatitis to multiple drugs. He was ultimately successfully treated with oral fusidic acid.

Case history

A twenty three year old patient presented with borderline lepromatous leprosy and mixed type lepra reactions. He developed acute drug induced hepatitis to dapsone, clofazimine and ofloxacin in combination and alone. The alternative drug minocycline is not available in Sri Lanka. Hence oral fusidic acid 500 mg daily was started. His initial bacillary index was 5 and morphological index was 4 and after completion of two months of treatment with fusidic acid it came down to 4 and 0 respectively.

Discussion

The WHO recommended chemotherapy for leprosy is well accepted, well tolerated¹ and has greatly helped in controlling the disease in our country. However, side effect such as drug induced hepatitis can cause problems. Drug-induced hepatitis is uncommon and generally unpredictable. Acute hepatocellular hepatitis may be severe enough to cause fulminant hepatitis, or of a more insidious course leading to cirrhosis. Cross hepatotoxicity can sometimes occur². One should be careful of re-administration of the causative drug or drugs with a related chemical structure³.

Dapsone, clofazimine and rifampicin carry a risk of inducing hepatitis. Also some patients can

develop hepatitis not only to above mentioned three drugs but also alternatives drugs such as fluoroquinolones (ofloxacin), macrolides (clarithromycin) and minocycline¹.

Under such circumstances physician faces the problem of finding a suitable alternative. Fusidic acid, both systemic and topical, has been used for a wide variety of less common infections including leprosy⁴. In some resistant cases successful outcome has been reported with 4 months of treatment with fusidic acid⁵. Our patient also responded well.

This case highlights the urgent need to find alternative therapy for leprosy.

References

1. Leprosy Elimination Group. The final push strategy to eliminate leprosy a public health problem. 2nd edition. Geneva: WHO, 2003.
2. Kumar P, Clark M. Liver, biliary tract and pancreatic disease. 5th edition, UK. Elsevier 2002; 384-7.
3. Kumar P, Clark M. Liver, biliary tract and pancreatic disease. 5th edition, UK. Elsevier 2002; 363.
4. Franzblau SG, Biswas AN, Harris EB. Fusidic acid is highly active against extracellular and intracellular *Mycobacterium leprae*. *Antimicrob Agents Chemother* 1992; 36(1): 92-4.
5. Franzblau SG, Chan GP, Garcia-Ignacio BG, Chavez VE, Livelio JB, et al. Clinical trial of fusidic acid for lepromatous leprosy. *Antimicrob Agents Chemother* 1994; 38(7): 1651-4.
6. Katoch K. New emerging drug regimens for leprosy. *Indian Journal of Dermatology, Venerology, Leprology* 1997; 3: 139-47.
7. Katoch K, Katoch VM, Natrajan M, Sharma VD. Chemotherapy trials in MB leprosy using conventional and newer drugs pefloxacin and minocycline. *Indian Journal of Dermatology, Venerology, Leprology* 2000; 66: 18-25.